Drug Aging
-
Anastrozole is a new oral nonsteroidal aromatase inhibitor indicated for the second-line endocrine treatment of postmenopausal women with advanced breast cancer. In postmenopausal women, anastrozole significantly reduces plasma estrogen levels; maximal suppression is achieved at dosages > or = 1 mg/day and levels remain suppressed during long term therapy. In two phase III clinical trials, anastrozole 1 or 10 mg/day showed similar clinical efficacy to that of oral megestrol (megestrol acetate) 160 mg/day in postmenopausal women with advanced breast cancer. Primary end-points [including time to disease progression (120 to 170 days) and overall response rates (complete and partial response and stable disease lasting > or = 24 weeks: 29 to 37%)] and secondary end-points [time to treatment failure (115 to 168 days) and duration of response (257 to 261 days)] did not differ significantly between treatment groups. However, a significant survival advantage was observed in patients treated with anastrozole 1 mg/day compared with megestrol in a follow-up combined analysis of patients enrolled in both studies (median time to death 26.7 vs 22.5 months). Quality of life parameters were generally improved to a similar extent in all treatment groups. Anastrozole is generally well tolerated in the majority of patients, the most common adverse events being gastrointestinal (GI) disturbances (incidence 29 to 33%). These events are generally mild or moderate and transient. Other adverse events reported with anastrozole include headache (< or = 18%), asthenia (< or = 16%), pain (< or = 15%), hot flushes and bone pain (both < or = 12%), back pain and dyspnoea (both < or = 11%) and peripheral oedema (< or = 9%). GI disturbance tended to be more common with anastrozole than megestrol, particularly at the 10 mg/day dosage; however, compared with megestrol, anastrozole is less frequently associated with weight gain. ⋯ Anastrozole, with its apparent survival advantage versus megestrol (demonstrated in a combined analysis of phase III studies), convenient once daily oral administration and acceptable short term tolerability profile, is a second-line treatment option for postmenopausal patients with tamoxifenrefractory advanced breast cancer. The results of ongoing comparative trials with tamoxifen will determine the relative efficacy of anastrozole as first-line endocrine therapy for advanced breast cancer and as adjuvant therapy for early disease. In addition, direct comparative studies are required to determine the efficacy of anastrozole relative to that of other oral aromatase inhibitors such as letrozole and vorozole.
-
The objective of this paper is to describe the ethics and incidence of euthanasia and physician-assisted suicide (EAS) with special regard to old age. It is based on an assumption that if and when a practice of euthanasia and EAS is allowed, several vulnerable groups, including the elderly, may become a 'population at risk'. We describe some of these claims, and make an inventory of the arguments against a permissive policy concerning euthanasia and EAS which emphasise inherent dangers for the elderly. ⋯ We conclude that, although euthanasia and assisted suicide are illegal, there is evidence that these practices occur in all countries studied. Most surveys on the incidence of euthanasia show lower figures than those in the Netherlands. Dutch studies do not provide any evidence for the elderly being in danger of becoming 'victims' of euthanasia or assisted suicide.
-
Delirium is common, morbid and costly, especially among hospitalised elderly patients. Nonetheless, it remains under-recognised and often poorly managed. This article summarises the 5 key steps in the optimal management of delirium. ⋯ This evaluation will usually involve a careful history, medication review, physical examination and selected laboratory testing. The fifth, and most important, step is the management of the delirious patient. The key elements of management are treating the primary condition(s) leading to delirium, removing all treatable contributing factors, maintaining behavioural control, and supporting the patient and their family.
-
Review Comparative Study
Practical guidelines on the postoperative use of patient-controlled analgesia in the elderly.
Inadequate pain control after surgery is associated with adverse outcomes in elderly patients; for this reason, effective analgesia is an essential component of postoperative care in this patient group. However, postoperative pain management is challenging in the elderly because of concomitant disease states and physiological factors that can affect the pharmacodynamic and pharmacokinetic properties of analgesic drugs. Patient-controlled analgesia (PCA) offers advantages over traditional intramuscular analgesia in this setting, because it provides the opportunity to tailor therapy to the individual, as opposed to the average, patient. ⋯ Education of patients and healthcare professionals alike is necessary to optimise the utility of PCA in older patients. In addition, every effort should be made to avoid the development of postoperative confusion, as this is associated with an increased risk of inefficient pain relief and its deleterious consequences. In summary, close monitoring and evaluation of the patient throughout the peri-operative periods is required to ensure the appropriate and successful use of PCA in elderly patients.
-
Antiarrhythmic drugs play a major role in the management of the most common types of arrhythmias. The margin between the beneficial and toxic effects of these drugs is often narrow. Thus, a precise knowledge of dosages, drug-target tissue interactions, pharmacodynamics and pharmacokinetics of antiarrhythmic drugs is needed to better predict how effective a particular drug will be in the treatment of a specific arrhythmia in a given patient. ⋯ The results of the Cardiac Arrhythmia Suppression Trial (CAST) firmly established that the use of class I drugs is potentially dangerous in a specific subset of patients. Additionally, several meta-analyses have reported that quinidine has severe proarrhythmic effects in patients with atrial fibrillation. The management of arrhythmias in elderly patients is difficult because of age-related factors that may influence the pharmacokinetics and pharmacodynamics of antiarrhythmic drugs.